Edition:
United Kingdom

Spring Bank Pharmaceuticals Inc (SBPH.OQ)

SBPH.OQ on NASDAQ Stock Exchange Capital Market

11.73USD
8:59pm GMT
Change (% chg)

$1.08 (+10.14%)
Prev Close
$10.65
Open
$10.51
Day's High
$11.80
Day's Low
$10.51
Volume
16,482
Avg. Vol
21,591
52-wk High
$18.59
52-wk Low
$8.91

Latest Key Developments (Source: Significant Developments)

Spring Bank Pharmaceuticals Q3 Loss Per Share $0.59
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Spring Bank Pharmaceuticals Inc ::SPRING BANK PHARMACEUTICALS REPORTS THIRD QUARTER FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.59.Q3 EARNINGS PER SHARE VIEW $-0.61 -- THOMSON REUTERS I/B/E/S.SPRING BANK PHARMACEUTICALS - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $71.3 MILLION AS OF SEPT 30.SPRING BANK PHARMACEUTICALS - EXPECTS EXISTING CASH, EQUIVALENTS & MARKETABLE SECURITIES WILL FUND OPERATING EXPENSES, CAPEX FOR AT LEAST 12 MONTHS.  Full Article

Spring Bank Announces Pricing Of Public Offering Of Common Stock
Thursday, 9 Aug 2018 

Aug 8 (Reuters) - Spring Bank Pharmaceuticals Inc ::SPRING BANK ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 3.00 MILLION COMMON SHARES PRICED AT $12.50PER SHARE.  Full Article

Spring Bank Announces Proposed Public Offering Of Common Stock
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Spring Bank Pharmaceuticals Inc ::SPRING BANK ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.INTENDS TO USE NET PROCEEDS FROM OFFERING TO FUND CLINICAL TRIALS, NONCLINICAL STUDIES, RESEARCH AND DEVELOPMENT.  Full Article

Spring Bank Announces Positive Study Results From The Inarigivir Achieve Trial
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Spring Bank Pharmaceuticals Inc ::SPRING BANK ANNOUNCES POSITIVE STUDY RESULTS FROM THE INARIGIVIR ACHIEVE TRIAL.SPRING BANK PHARMACEUTICALS - EXPANSION OF PHASE 2 CLINICAL TRIAL BEING UNDERTAKEN BY GILEAD SCIENCES.SPRING BANK PHARMACEUTICALS - TWO ADDITIONAL COHORTS ADDED TO HBV CLINICAL PROGRAM FOR INARIGIVIR CO-ADMINISTERED WITH GILEAD'S TENOFOVIR ALAFENAMIDE.SPRING BANK PHARMACEUTICALS INC - INARIGIVIR CLINICAL PROGRAM ACCELERATED TO ENTER MULTIPLE GLOBAL PHASE 2B/3 TRIALS IN EARLY 2019.SPRING BANK PHARMACEUTICALS INC - CONTINUES TO EXPLORE COLLABORATIONS, INCLUDING WITH SIRNA COMPOUNDS TARGETING HBSAG.SPRING BANK PHARMACEUTICALS INC - PRIMARY ENDPOINTS, SAFETY AND ANTIVIRAL ACTIVITY, WERE ACHIEVED AT BOTH WEEK 12 (INARIGIVIR MONOTHERAPY) AND WEEK 24.SPRING BANK PHARMACEUTICALS INC - INARIGIVIR WAS WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS OBSERVED.SPRING BANK PHARMA - ANTICIPATES INARIGIVIR WILL BE INCLUDED IN "TRIPLE COMBINATION" CLINICAL TRIAL WITH SIRNA COMPOUND/DIFFERENT MECHANISM IN H1 2019.  Full Article

Spring Bank Pharmaceuticals announces positive top-line results from the second cohort of part A of the phase 2 achieve trial
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Spring Bank Pharmaceuticals Inc :Spring Bank Pharmaceuticals announces positive top-line results from the second cohort of part A of the phase 2 achieve trial.Spring Bank Pharmaceuticals - ‍Inarigivir 50mg daily for 12 weeks met both primary endpoints of safety and efficacy in second cohort of achieve trial​.Spring Bank Pharmaceuticals - ‍inarigivir demonstrated a statistically significant reduction in hbv dna at week 12 compared to combined placebo group​.Spring Bank Pharma - sees Gilead initiating Phase 2 trial examining co-administration of inarigivir, vemlidy​ for infections with chronic HBV in Q1 2018.  Full Article

Spring Bank Pharmaceuticals - Q3 loss per share $0.85
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Spring Bank Pharmaceuticals Inc :Spring Bank Pharmaceuticals provides corporate update and reports third quarter 2017 financial and operational results.Q3 loss per share $0.85.Q3 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S.Spring Bank Pharmaceuticals - top-line results from second inarigivir monotherapy dosing cohort of achieve trial will be released in Q4 2017​.Spring Bank Pharmaceuticals - expects existing cash, cash equivalents, marketable securities will enable co to fund expenses, capex through 2019-end.Spring Bank - expects cash, cash equivalents, marketable securities will not be enough to fund development of inarigivir beyond Phase 2 achieve trial​.  Full Article

Spring Bank Pharmaceuticals Q4 loss per share $0.28
Wednesday, 15 Feb 2017 

Spring Bank Pharmaceuticals Inc : Spring Bank Pharmaceuticals provides corporate update and reports 2016 financial and operational results .Q4 loss per share $0.28.  Full Article